Businessoffashion

Zepbound Beats Wegovy in First Head-to-Head Trial

Eli Lilly's GLP-1 drug Zepbound helped nearly 25 percent more participants lose weight than Novo Nordisk's Wegovy, according to the trial results.

May 12, 2025 - 17:05
 0
Zepbound Beats Wegovy in First Head-to-Head Trial
Eli Lilly's GLP-1 drug Zepbound helped nearly 25 percent more participants lose weight than Novo Nordisk's Wegovy, according to the trial results.
Read More

Tags:

Previous Article

How to Wear a Polo Shirt Without Looking Like a Middle Manager

Next Article

Joe Doucet's OLO Table Gives New Life to Old Refrigerators, Keyboards and Comput...

Related Posts

US Retailers Want in on K-Beauty — Again

US Retailers Want in on K-Beauty — Again

May 7, 2025  0

Reebok Names New Head of Basketball

Reebok Names New Head of Basketball

May 6, 2025  0

When Two CEOs Are Better Than One

When Two CEOs Are Better Than One

Apr 21, 2025  0